MX2020006840A - Composicion farmaceutica que comprende un peptido tipo apl. - Google Patents

Composicion farmaceutica que comprende un peptido tipo apl.

Info

Publication number
MX2020006840A
MX2020006840A MX2020006840A MX2020006840A MX2020006840A MX 2020006840 A MX2020006840 A MX 2020006840A MX 2020006840 A MX2020006840 A MX 2020006840A MX 2020006840 A MX2020006840 A MX 2020006840A MX 2020006840 A MX2020006840 A MX 2020006840A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
apl peptide
seq
treatment
relates
Prior art date
Application number
MX2020006840A
Other languages
English (en)
Inventor
Abad Cruz Matilde Lopez
Horta Marí­A Del Carmen Domínguez
López Luis Javier González
Pérez Vladimir Armando Besada
Original Assignee
Ct Ingenieria Genetica Biotecnologia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotecnologia filed Critical Ct Ingenieria Genetica Biotecnologia
Publication of MX2020006840A publication Critical patent/MX2020006840A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6043—Heat shock proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invencion provee una composicion farmaceutica que comprende el peptido tipo APL identificado como SEQ ID No. 1, el tampon acetato de sodio a pH 3,9 - 4,7; y al menos un azucar estabilizante seleccionado entre la sacarosa y la trehalosa; dicha composicion farmaceutica esutil para el tratamiento de las enfermedades inflamatorias relacionadas con un aumento de los neutrofilos o de la citrulinacion de proteinas; entre estas enfermedades inflamatorias se encuentran la artritis reumatoide (AR), la artritis idiopatica juvenil (AIJ), la espondilitis anquilosante (EA), la enfermedad de Alzheimer, y la fibrosis hepatica o pulmonar; la invencion tambien revela un métodopara el tratamiento de dichas enfermedades, mediante la administracion de una cantidad terapeuticamente efectiva de la composicion farmaceutica del peptido tipo APL identificado como SEQ ID No. 1.
MX2020006840A 2017-12-29 2018-12-21 Composicion farmaceutica que comprende un peptido tipo apl. MX2020006840A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU2017000176A CU24508B1 (es) 2017-12-29 2017-12-29 Composición farmacéutica que comprende péptido tipo apl
PCT/CU2018/050007 WO2019129315A1 (es) 2017-12-29 2018-12-21 Composición farmaceutica que comprende un peptido tipo apl

Publications (1)

Publication Number Publication Date
MX2020006840A true MX2020006840A (es) 2020-09-03

Family

ID=65351834

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020006840A MX2020006840A (es) 2017-12-29 2018-12-21 Composicion farmaceutica que comprende un peptido tipo apl.

Country Status (13)

Country Link
US (1) US20200353040A1 (es)
EP (1) EP3733196B1 (es)
JP (1) JP7209000B2 (es)
KR (1) KR102676701B1 (es)
CN (1) CN111741763B (es)
AR (1) AR114389A1 (es)
BR (1) BR112020013033A2 (es)
CA (1) CA3086280A1 (es)
CU (1) CU24508B1 (es)
ES (1) ES2960415T3 (es)
MX (1) MX2020006840A (es)
WO (1) WO2019129315A1 (es)
ZA (1) ZA202004658B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220281943A1 (en) * 2019-08-14 2022-09-08 The Regents Of The University Of California Car-t cells specific for modified proteins in extracellular spaces
CU24626B1 (es) 2019-12-26 2022-11-07 Centro Nac De Biopreparados Composición farmacéutica a base de proteínas con actividad neuroprotectora, inmunomoduladora, antiinflamatoria y antimicrobiana
CU20200026A7 (es) * 2020-04-13 2021-11-04 Ct Ingenieria Genetica Biotecnologia Péptido para el tratamiento del síndrome de la tormenta de citocinas
CN111870697B (zh) * 2020-09-18 2022-09-09 山东鲁抗医药股份有限公司 糖类物质在提高apl型衍生肽稳定性中的应用和冻干组合物
WO2024017423A1 (es) * 2022-07-22 2024-01-25 Centro De Ingenieria Genética Y Biotecnología Péptido para el tratamiento de enfermedades relacionadas con afectaciones en la apolipoproteina ai o la transtirretina

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23504A1 (es) * 2004-09-24 2010-04-13 Ct Ingenieria Genetica Biotech Péptidos y derivados tipo apl de la hsp60 y composiciones farmacéuticas
AU2007240732B2 (en) * 2006-04-21 2013-07-04 Amgen, Inc. Buffering agents for biopharmaceutical formulations
WO2009090650A2 (en) 2008-01-16 2009-07-23 Ben-Gurion University Of The Negev Research And Development Authority Vaccine for alzheimer's disease
JP5528436B2 (ja) * 2008-06-04 2014-06-25 モディクエスト べー．フェー． 抗炎症剤
CU23701A1 (es) * 2008-12-29 2011-09-21 Ct Ingenieria Genetica Biotech Método de tratamiento de enfermedades inflamatorias intestinales y diabetes tipo i

Also Published As

Publication number Publication date
EP3733196A1 (en) 2020-11-04
CA3086280A1 (en) 2019-07-04
EP3733196B1 (en) 2023-08-30
JP7209000B2 (ja) 2023-01-19
CU20170176A7 (es) 2019-08-06
AR114389A1 (es) 2020-09-02
BR112020013033A2 (pt) 2020-12-01
CU24508B1 (es) 2021-04-07
RU2020124953A (ru) 2022-01-31
RU2020124953A3 (es) 2022-01-31
JP2021508711A (ja) 2021-03-11
CN111741763A (zh) 2020-10-02
ZA202004658B (en) 2022-01-26
CN111741763B (zh) 2024-06-14
KR102676701B1 (ko) 2024-06-20
ES2960415T3 (es) 2024-03-04
WO2019129315A1 (es) 2019-07-04
US20200353040A1 (en) 2020-11-12
KR20200105869A (ko) 2020-09-09

Similar Documents

Publication Publication Date Title
MX2020006840A (es) Composicion farmaceutica que comprende un peptido tipo apl.
MX2021006615A (es) Proteinas de union triespecificas y metodos de uso.
EA202192588A1 (ru) Фармацевтическая композиция, включающая вариант ph20 гиалуронидазы человека, и лекарственное средство для подкожного введения
MX2018010824A (es) Proteinas de union inducibles y metodos de uso.
MX2021003554A (es) Proteinas de union a dll3 y metodos de uso.
NZ725360A (en) Liquid pharmaceutical composition
AU2017263237A1 (en) GDF15 fusion proteins and uses thereof
PH12020550881A1 (en) Substituted bicyclic heterocyclic compounds as prmt5 inhibitors
JP2015517489A5 (es)
EA025267B1 (ru) Водная фармацевтическая композиция этанерцепта, стабилизированная глутаматом
JP2014221758A5 (es)
PH12017501118A1 (en) Pharmaceutical composition comprising plasminogen and uses thereof
MX2018006635A (es) Agonistas del receptor 2 de formilpeptido y del receptor 1 de formilpeptido, de piperidinona.
PH12020551096A1 (en) A modified raav capsid protein for gene therapy
BR112022002387A2 (pt) Composto da fórmula z-y-q-y' ou um sal ou éster farmaceuticamente aceitável do mesmo
RU2017101667A (ru) Фармацевтические композиции
MX2022004146A (es) Composición farmacéutica de vector de virus adenoasociado y métodos.
JP2015513318A5 (es)
MX2020008096A (es) Peptidos de la cadena b de la relaxina lipidados modificados y su uso terapeutico.
IN2014DN06920A (es)
JP2016513471A5 (es)
JP2019501920A5 (es)
PE20210918A1 (es) Composiciones y metodos para el tratamiento de la distrofia macular
MX2018006269A (es) Anticuerpo anti-alfa-v-integrina para el tratamiento de fibrosis y/o trastornos fibroticos.
MX2022006735A (es) Análogos de nucleósidos sustituidos como inhibidores de la prmt5.